Business Context and Reporting Period
Oncolytics Biotech Inc., a foreign private issuer based in Calgary, Alberta, Canada, filed Form 6-K for the month of June 2018. The filing primarily serves to distribute two press releases dated June 1, 2018, regarding significant corporate actions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on capital market activities rather than operational financial performance.
- Capital Raised: USD $8,000,000 from a public offering of common shares.
- Listing Status: Announced listing on the Nasdaq Capital Market.
Material Changes
The primary material change reported is the successful pricing of a public offering of common shares totaling USD $8,000,000. Concurrently, the company announced its listing on the Nasdaq Capital Market, marking a significant change in its trading venue and market access.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on future operations, or a detailed discussion of risks and contingencies beyond the context of the capital raise and listing. No unusual items were disclosed in the provided text.
Investor Verification Checklist
- Verify the final closing date and net proceeds of the USD $8,000,000 public offering.
- Confirm the ticker symbol and trading commencement date on the Nasdaq Capital Market.
- Review the full press releases (Exhibit 99.1) for details on the use of proceeds from the offering.
- Check subsequent filings for updated cash position following the capital raise.